Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2016 - 2025)

Fennec Pharmaceuticals' Cash from Financing Activities history spans 14 years, with the latest figure at $20.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 270.35% year-over-year to $20.8 million, compared with a TTM value of $22.6 million through Dec 2025, up 266.19%, and an annual FY2025 reading of $22.6 million, up 266.19% over the prior year.
  • Cash from Financing Activities for Q4 2025 was $20.8 million at Fennec Pharmaceuticals, up from $1.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $20.8 million in Q4 2025, with the low at -$12.2 million in Q4 2024.
  • Average Cash from Financing Activities over 4 years is $2.3 million, with a median of $229000.0 recorded in 2023.
  • Year-over-year, Cash from Financing Activities soared 1186.67% in 2023 and then crashed 686.53% in 2024.
  • Tracing FENC's Cash from Financing Activities over 4 years: stood at $824000.0 in 2022, then soared by 595.39% to $5.7 million in 2023, then plummeted by 313.12% to -$12.2 million in 2024, then surged by 270.35% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Cash from Financing Activities are $20.8 million (Q4 2025), $1.7 million (Q3 2025), and -$284000.0 (Q2 2025).